WEKO3
アイテム
{"_buckets": {"deposit": "25ec8c71-d377-485b-82b2-9b5582c0737e"}, "_deposit": {"created_by": 1, "id": "47415", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "47415"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00047415", "sets": ["1"]}, "author_link": ["474779", "474778", "474771", "474768", "474777", "474774", "474773", "474767", "474772", "474775", "474770", "474780", "474769", "474776"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "358", "bibliographicPageStart": "349", "bibliographicVolumeNumber": "30", "bibliographic_titles": [{"bibliographic_title": "Cancer biotherapy \u0026 radiopharmaceuticals"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "(111)In-labeled trastuzumab modified with nuclear localizing signal (NLS) peptides ((111)In-trastuzumab-NLS) efficiently delivers an Auger electron (AE) emitter (111)In into the cell nucleus and is thus a promising radiopharmaceutical in AE radioimmunotherapy (AE-RIT) for targeted killing of HER2-positive cancer. However, further improvement of its therapeutic efficacy is required. In this study, the authors show a transcriptomic approach to identify potential targets for enhancing the cytotoxic effects of (111)In-trastuzumab-NLS. They generated two types of (111)In-trastuzumab-NLS harboring different numbers of NLS peptides, (111)In-trastuzumab-NLS-S and -L. These radioimmunoconjugates (230 and 460 kBq) showed a significant higher cytotoxicity to SKBR3 human breast cancer cells overexpressing HER2 compared to (111)In-trastuzumab. Microarray analysis revealed that NF-kB-related genes (38 genes) were significantly changed in transcription by (111)In trastuzumab-NLS-L (230 kBq) treatment. Quantitative reverse transcription polymerase chain reaction confirmed the microarray data by showing transcriptional alternation of selected NF-κB target genes in cells treated with (111)In-trastuzumab-NLS-L. Interestingly, bortezomib, a drug known as a NF-κB modulator, significantly enhanced the cytotoxicity of (111)In-trastuzumab-NLS-L in SKBR3 cells. Taken together, the transcriptome data suggest the possibility that the modulation of NF-kB signaling activity is a molecular signature of (111)In-trastuzumab-NLS and coadministration of bortezomib may be efficacious in enhancement of AE-RIT with (111)In-trastuzumab-NLS.", "subitem_description_type": "Abstract"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "26447839", "subitem_relation_type_select": "PMID"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1084-9785", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Keiko, Li Huizi"}], "nameIdentifiers": [{"nameIdentifier": "474767", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morokoshi, Yukie"}], "nameIdentifiers": [{"nameIdentifier": "474768", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Daino, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "474769", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furukawa, Takako"}], "nameIdentifiers": [{"nameIdentifier": "474770", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "474771", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "474772", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hasegawa, Sumitaka"}], "nameIdentifiers": [{"nameIdentifier": "474773", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "李 惠子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "474774", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "諸越 幸恵", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "474775", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "臺野 和広", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "474776", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "古川 高子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "474777", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鎌田 正", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "474778", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐賀 恒夫", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "474779", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "長谷川 純崇", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "474780", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies."}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/47415", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-05-18"}, "publish_date": "2016-05-18", "publish_status": "0", "recid": "47415", "relation": {}, "relation_version_is_last": true, "title": ["Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies."], "weko_shared_id": -1}
Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies.
https://repo.qst.go.jp/records/47415
https://repo.qst.go.jp/records/4741575731587-f1d7-4ebc-a172-0476bb7f399d
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-05-18 | |||||
タイトル | ||||||
タイトル | Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Keiko, Li Huizi
× Keiko, Li Huizi× Morokoshi, Yukie× Daino, Kazuhiro× Furukawa, Takako× Kamada, Tadashi× Saga, Tsuneo× Hasegawa, Sumitaka× 李 惠子× 諸越 幸恵× 臺野 和広× 古川 高子× 鎌田 正× 佐賀 恒夫× 長谷川 純崇 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | (111)In-labeled trastuzumab modified with nuclear localizing signal (NLS) peptides ((111)In-trastuzumab-NLS) efficiently delivers an Auger electron (AE) emitter (111)In into the cell nucleus and is thus a promising radiopharmaceutical in AE radioimmunotherapy (AE-RIT) for targeted killing of HER2-positive cancer. However, further improvement of its therapeutic efficacy is required. In this study, the authors show a transcriptomic approach to identify potential targets for enhancing the cytotoxic effects of (111)In-trastuzumab-NLS. They generated two types of (111)In-trastuzumab-NLS harboring different numbers of NLS peptides, (111)In-trastuzumab-NLS-S and -L. These radioimmunoconjugates (230 and 460 kBq) showed a significant higher cytotoxicity to SKBR3 human breast cancer cells overexpressing HER2 compared to (111)In-trastuzumab. Microarray analysis revealed that NF-kB-related genes (38 genes) were significantly changed in transcription by (111)In trastuzumab-NLS-L (230 kBq) treatment. Quantitative reverse transcription polymerase chain reaction confirmed the microarray data by showing transcriptional alternation of selected NF-κB target genes in cells treated with (111)In-trastuzumab-NLS-L. Interestingly, bortezomib, a drug known as a NF-κB modulator, significantly enhanced the cytotoxicity of (111)In-trastuzumab-NLS-L in SKBR3 cells. Taken together, the transcriptome data suggest the possibility that the modulation of NF-kB signaling activity is a molecular signature of (111)In-trastuzumab-NLS and coadministration of bortezomib may be efficacious in enhancement of AE-RIT with (111)In-trastuzumab-NLS. | |||||
書誌情報 |
Cancer biotherapy & radiopharmaceuticals 巻 30, 号 8, p. 349-358, 発行日 2015-10 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1084-9785 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 26447839 |